Purva Sethi

Dynamic professional with a robust background in biomarker development, immunoassays, nanoparticle development and stem cell research. Expert in clinical trial coordination and stem cell culture techniques, complemented by strong skills in scientific communication and digital marketing. Proven track record of driving awareness and achieving regulatory compliance, showcasing a blend of technical proficiency and strategic acumen. Networked with elite research teams from Switzerland, Italy and Phoenix scientific institutions to develop and improve research protocols for biomarker development. Conducted complicated research with integrity and great attention to detail.

Shree Pacetronix Pvt.Ltd./Biopace technology -India/USA : Assisted Pacemaker Implantation in order to help the poor patients in need in India,Indore.

Choitram Charitable Hospital-India,Indore: Teaching Pathology to nurses and developing their skill for better healthcare practice.

PhD Project: Synthesis and Characterization of novel nanoparticles and studies on their interactions with Stem cells

This study basically focused on detailed cellular interactions of human serum albumin coated iron oxide nanoparticles (HSA-IONPs) with the umbilical cord derived human mesenchymal stem cells (hUC-MSCs). It highlights minimum membrane damage and mitochondrial impairment post internalization which was further confirmed by the lowest detection of reactive oxygen species after HSA-IONPs internalization.

further, the labeling of the isolated stem cells did not alter the cytoskeletal integrity and morphology of hUC-MSCs. The MRI analysis also proved the maintenance of contrast signal generation even after 28 days in differentiated hUC-MSCs.

HSA-IONPs proved to be promising alternative for future pre-clinical studies in comparison to the other commercially available IONPs for stem cell based therapies in labeling and tracking the transplanted cells.

• Sanganeria P, Sachar S, Chandra S, Bahadur D, Ray P & Khanna A. 2015. Cellular internalization and detailed toxicity analysis of protein immobilized iron oxide nanoparticles. J Biomed Mater Part B:Appl Biomater, 103B: 125-134. (IF=3.18)
• Sanganeria P, Sachar S, Chandra S, Bahadur D, Ray P & Khanna A. 2015. Effect of HSA coated iron oxide labeling on human umbilical cord derived mesenchymal stem cells. Nanotechnology, 26(12), 125103. (IF=3.82)
• Ashish S, Rodriguez RR, Sethi P, Yu F, Raj M. Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma. Cureus. 2022 Oct 4;14(10):e29922. doi: 10.7759/cureus.29922. PMID: 36348885; PMCID: PMC9633320.

• Participated in annual Target-ALS Meeting, Boston 7th -9th May, 2024.
• Live podium presentation at KCU’s 2024 Research Symposium 2nd -5thApril, 2024.
• Participated in annual Target-ALS Meeting, Boston 5th -7th May, 2023.
• Invited as Speaker at, "World Summit on Stem Cells and Immunotechnology" organized by Shunxi Stem Cell and Regenerative Medicine, kunming, Yunnan Province, China-2017.
• Best Poster Award received at International Conference on Nanoscience and Technology (ICONSAT-2014), India
• Post graduate diploma in German Language
• Diploma in Biostatistics

USA Citizenship (2024)